Invest in Baobab Biopharma: Pioneering Health Sovereignty in Africa
Join us in revolutionizing African healthcare through a rare dual opportunity, access to a high-growth, underserved market while advancing health independence across the continent.
"Africa's health sovereignty isn't aspirational, it's imperative. At Baobab, we're creating high-quality affordable medicines by Africans, for Africans. This isn't just business, it's Africa controlling its pharmaceutical destiny while delivering exceptional returns for investors."
Dr. Yves SERE, Co-Founder
The Challenge We are Solving
Africa's healthcare faces critical vulnerabilities:
-
🏥 90% of medicines and 99% of vaccines are imported.
-
💊 50% of Africans lack access to essential medicines.
-
💰 Up to 70% cannot afford critical medications.
-
⚠️ 39% of medicines fail quality standards, leading to preventable deaths.
-
🌍 Africa bears 25% of the global disease burden, but lacks pharmaceutical infrastructure.
COVID-19 exposed the urgent need for local manufacturing. Baobab is the solution.
Market Opportunity: A $6+ Billion Imperative
Addressing Critical Health Needs:
-
$6B+ Market: Targeting malaria & antibiotic segments with 4% annual growth.
-
Massive Demand: Serving 247M malaria cases and millions of bacterial infections.
-
Africa’s healthcare spending will surge 3.5× to $4.75 trillion by 2050, driven by population growth.
Expanding Our Market Impact
Baobab’s future portfolio includes high-growth pharmaceutical segments across Africa:
-
Biosimilars: $2B market, 29.79% CAGR, reaching $5B+ in a decade.
-
Vaccines: From $1.3B to $4.7B by 2030, with Africa demanding 37% of global supply.
-
IV Fluids: Growing 8.3% CAGR, strengthening Africa’s healthcare infrastructure.
Why Invest In Baobab?
Robust Five-Year Financial Outlook
-
See chart: Projected $173.8M revenue & $131M net profit by Year 5.
-
15-20% cost savings through localized production
-
12-15M patients served annually, 750+ quality jobs created
Strategic Investment Allocation
-
See pie chart: $58.6M manufacturing, $12.3M R&D, $30.3M operations.
The Baobab Advantage
✅ Cost Leadership: 15–20% lower costs than imports, ensuring affordability.
✅ Uncompromising Quality: WHO pre-qualified, meeting global standards.
✅ First-Mover Edge: Establishing Burkina Faso’s pharmaceutical hub.
✅ Supply Chain Security: Reducing import reliance, strengthening healthcare resilience.
Regulatory Tailwinds: A Supportive Policy Environment
Baobab aligns with Africa’s top healthcare initiatives:
-
Africa CDC: Supports local pharmaceutical manufacturing.
-
African Union’s 2030 Plan: Targeting 70% local medicine production.
-
African Medicines Regulatory Harmonization: Faster approvals across Africa.
-
AfDB’s $3B Investment: Backing pharmaceutical infrastructure development.